Martin Dieck

Mr. Dieck has co-founded and held senior management positions in four neuro-interventional companies, all of which were acquired by Medtronic, Covidien or Stryker. Currently Mr. Dieck is Chairman of Synchron, Inc. a neuro-interventional company developing a minimally invasive brain machine interface. Mr. Dieck was co-founder, Chairman and CEO of Lazarus Effect, which developed a next-generation stroke treatment device and was sold to Medtronic in 2015. He previously served as CEO and board member at Nfocus Neuromedical, and Concentric Medical. As a venture investor, Mr. Dieck was an Executive Director at DFJ-ePlanet and ePlanet Capital where he had direct responsibility for the med-tech portfolio. This portfolio included BodyMedia (sold to Aliphcom / Jawbone), Spinal Modulation (sold to St Jude Medical), Zonare (sold to Mindray), DirectFlow and Intrapace. Mr. Dieck is an inventor with over 30 issued and pending patents. He received his BA in Biological Sciences from Willamette University and MBA from the University of California at Berkeley.